SOPHiA GENETICS SA (NASDAQ:SOPH) Q2 2022 Results Conference Call August 9, 2022 8:30 AM ET Company Participants Jennifer Pottage - Head, IR Dr. Jurgi Camblong - Co-Founder and CEO Ross Muken - CFO Conference Call Participants Julia Qin - JP Morgan Vidyun Bais - BTIG Kyle Boucher - Cowen Operator Good day, and welcome to the SOPHiA GENETICS Second Fiscal Quarter 2022 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference over to Jennifer Pottage, Head of Investor Relations. ...

Exhibit 99.1 Index to Consolidated Financial Statements Table of Contents | | Unaudited Interim Condensed Consolidated Financial Statements | F-2 | | --- | --- | --- | | – | Unaudited Interim Condensed Consolidated Statements of Loss | F-3 | | – | Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss | F-4 | | – | Unaudited Interim Condensed Consolidated Balance Sheets | F-5 | | – | Unaudited Interim Condensed Consolidated Statements of Changes in Equity | F-6 | | – | Unaudited Interim C ...

SOPHiA GENETICS SA (NASDAQ:SOPH) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Jennifer Pottage - Head of IR Jurgi Camblong - Co-Founder, CEO and Director Ross Muken - Senior VP and CFO Conference Call Participants Dan Brennan - Cowen Tejas Savant - Morgan Stanley Julia Chen - JPMorgan Operator Thank you for standing by, and welcome to the SOPHiA GENETICS First Quarter Fiscal 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the sp ...

Investor Presentation First Quarter Fiscal 2022 Cautionary Notices This presentation contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, products and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forwardlooking statements are based on ou ...

SOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2021 Earnings Conference Call March 15, 2022 8:30 AM ET Company Participants Jennifer Pottage - Head of IR Jurgi Camblong - Founder and CEO Ross Muken - CFO Peter Casasanto - Chief BioPharma Officer Conference Call Participants Tejas Savant - Morgan Stanley Mark Massaro - BTIG Daniel Brennan - Cowen and Company Unidentified Analyst - J.P. Morgan Operator Ladies and gentlemen, thank you for standing by and welcome to the SOPHiA GENETICS Fourth Quarter 2021 Earnings Confere ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 SOPHiA GENETICS SA (Exact name of Registrant as specified in its charter) Switzerland (Jurisdi ...

Exhibit 99.3 SOPHiA GENETICS SA Saint-Sulpice Report of the statutory auditor to the General Meeting on the consolidated financial statements 2021 Report of the statutory auditor to the General Meeting of SOPHiA GENETICS SA Saint-Sulpice Report on the audit of the consolidated financial statements Opinion We have audited the consolidated financial statements of SOPHiA GENETICS SA and its subsidiaries (the Group), which comprise the consolidated statements of loss and the consolidated statements of comprehen ...

Exhibit 99.3 SOPHiA GENETICS SA Saint-Sulpice Report of the statutory auditor to the General Meeting on the consolidated financial statements 2021 Report of the statutory auditor to the General Meeting of SOPHiA GENETICS SA Saint-Sulpice Report on the audit of the consolidated financial statements Opinion We have audited the consolidated financial statements of SOPHiA GENETICS SA and its subsidiaries (the Group), which comprise the consolidated statements of loss and the consolidated statements of comprehen ...

| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|---------------------------------------------------------------------------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Democratizing | | | | | | | | | | | | | Data-Driven Medicine | | | | | | | | | | | | | Together | | | | | | | | | | | | | | | | | | | | | | | | | ...

SOPHiA GENETICS SA (NASDAQ:SOPH) Q3 2021 Earnings Conference Call November 10, 2021 8:30 AM ET Company Participants Jurgi Camblong - Co-Founder & Chief Executive Officer Lara Hashimoto - Chief Business Officer Ross Muken - Chief Financial Officer Philippe Menu - Chief Medical Officer Conference Call Participants Tycho Peterson - JP Morgan Dan Brennan - Cowen & Company Operator Good day and thank you for standing by. Welcome to the SOPHiA GENETICS Third Quarter 2021 Earnings Conference Call. At this time, al ...